Exercise hemodynamics in heart failure patients with preserved and mid-range ejection fraction: key role of the right heart.

Exercise hemodynamics Heart failure with mid-range ejection fraction Heart failure with preserved ejection fraction Right heart TAPSE/PASP ratio

Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
Apr 2022
Historique:
received: 29 08 2020
accepted: 27 05 2021
pubmed: 11 6 2021
medline: 5 4 2022
entrez: 10 6 2021
Statut: ppublish

Résumé

We sought to explore whether classification of patients with heart failure and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) according to their left ventricular ejection fraction (LVEF) identifies differences in their exercise hemodynamic profile, and whether classification according to an index of right ventricular (RV) function improves differentiation. Patients with HFmrEF and HFpEF have hemodynamic compromise on exertion. The classification according to LVEF implies a key role of the left ventricle. However, RV involvement in exercise limitation is increasingly recognized. The tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/PASP) ratio is an index of RV and pulmonary vascular function. Whether exercise hemodynamics differ more between HFmrEF and HFpEF than between TAPSE/PASP tertiles is unknown. We analyzed 166 patients with HFpEF (LVEF ≥ 50%) or HFmrEF (LVEF 40-49%) who underwent basic diagnostics (laboratory testing, echocardiography at rest, and cardiopulmonary exercise testing [CPET]) and exercise with right heart catheterization. Hemodynamics were compared according to echocardiographic left ventricular or RV function. Exercise hemodynamics (e.g. pulmonary arterial wedge pressure/cardiac output [CO] slope, CO increase during exercise, and maximum total pulmonary resistance) showed no difference between HFpEF and HFmrEF, but significantly differed across TAPSE/PASP tertiles and were associated with CPET results. N-terminal pro-brain natriuretic peptide concentration also differed significantly across TAPSE/PASP tertiles but not between HFpEF and HFmrEF. In patients with HFpEF or HFmrEF, TAPSE/PASP emerged as a more appropriate stratification parameter than LVEF to predict clinically relevant impairment of exercise hemodynamics. Stratification of exercise hemodynamics in patients with HFpEF or HFmrEF according to LVEF or TAPSE/PASP, showing significant distinctions only with the RV-based strategy. All data are shown as median [upper limit of interquartile range] and were calculated using the independent-samples Mann-Whitney U test or Kruskal-Wallis test. PVR pulmonary vascular resistance; max maximum level during exercise.

Sections du résumé

OBJECTIVE OBJECTIVE
We sought to explore whether classification of patients with heart failure and mid-range (HFmrEF) or preserved ejection fraction (HFpEF) according to their left ventricular ejection fraction (LVEF) identifies differences in their exercise hemodynamic profile, and whether classification according to an index of right ventricular (RV) function improves differentiation.
BACKGROUND BACKGROUND
Patients with HFmrEF and HFpEF have hemodynamic compromise on exertion. The classification according to LVEF implies a key role of the left ventricle. However, RV involvement in exercise limitation is increasingly recognized. The tricuspid annular plane systolic excursion/systolic pulmonary arterial pressure (TAPSE/PASP) ratio is an index of RV and pulmonary vascular function. Whether exercise hemodynamics differ more between HFmrEF and HFpEF than between TAPSE/PASP tertiles is unknown.
METHODS METHODS
We analyzed 166 patients with HFpEF (LVEF ≥ 50%) or HFmrEF (LVEF 40-49%) who underwent basic diagnostics (laboratory testing, echocardiography at rest, and cardiopulmonary exercise testing [CPET]) and exercise with right heart catheterization. Hemodynamics were compared according to echocardiographic left ventricular or RV function.
RESULTS RESULTS
Exercise hemodynamics (e.g. pulmonary arterial wedge pressure/cardiac output [CO] slope, CO increase during exercise, and maximum total pulmonary resistance) showed no difference between HFpEF and HFmrEF, but significantly differed across TAPSE/PASP tertiles and were associated with CPET results. N-terminal pro-brain natriuretic peptide concentration also differed significantly across TAPSE/PASP tertiles but not between HFpEF and HFmrEF.
CONCLUSION CONCLUSIONS
In patients with HFpEF or HFmrEF, TAPSE/PASP emerged as a more appropriate stratification parameter than LVEF to predict clinically relevant impairment of exercise hemodynamics. Stratification of exercise hemodynamics in patients with HFpEF or HFmrEF according to LVEF or TAPSE/PASP, showing significant distinctions only with the RV-based strategy. All data are shown as median [upper limit of interquartile range] and were calculated using the independent-samples Mann-Whitney U test or Kruskal-Wallis test. PVR pulmonary vascular resistance; max maximum level during exercise.

Identifiants

pubmed: 34110459
doi: 10.1007/s00392-021-01884-1
pii: 10.1007/s00392-021-01884-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

393-405

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 268555672

Informations de copyright

© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer PTF, Authors/Task Force Members (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 37(27):2129–2200. https://doi.org/10.1093/eurheartj/ehw128
doi: 10.1093/eurheartj/ehw128
Nauta JF, Hummel YM, van Melle JP, van der Meer P, Lam CSP, Ponikowski P, Voors AA (2017) What have we learned about heart failure with mid-range ejection fraction one year after its introduction? Eur J Heart Fail 19(12):1569–1573. https://doi.org/10.1002/ejhf.1058
doi: 10.1002/ejhf.1058 pubmed: 29067761
Rickenbacher P, Kaufmann BA, Maeder MT, Bernheim A, Goetschalckx K, Pfister O, Pfisterer M, Brunner-La Rocca HP, TIME-CHF Investigators (2017) Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail. https://doi.org/10.1002/ejhf.798
doi: 10.1002/ejhf.798 pubmed: 28295985
Bristow MR, Kao DP, Breathett KK, Altman NL, Gorcsan J 3rd, Gill EA, Lowes BD, Gilbert EM, Quaife RA, Mann DL (2017) Structural and functional phenotyping of the failing heart: is the left ventricular ejection fraction obsolete? JACC Heart failure 5(11):772–781. https://doi.org/10.1016/j.jchf.2017.09.009
doi: 10.1016/j.jchf.2017.09.009 pubmed: 29096787 pmcid: 7340335
Mele D, Nardozza M, Ferrari R (2018) Left ventricular ejection fraction and heart failure: an indissoluble marriage? Eur J Heart Fail 20(3):427–430. https://doi.org/10.1002/ejhf.1071
doi: 10.1002/ejhf.1071 pubmed: 29314500
Corra U, Agostoni PG, Anker SD, Coats AJS, Crespo Leiro MG, de Boer RA, Harjola VP, Hill L, Lainscak M, Lund LH, Metra M, Ponikowski P, Riley J, Seferovic PM, Piepoli MF (2018) Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20(1):3–15. https://doi.org/10.1002/ejhf.979
doi: 10.1002/ejhf.979 pubmed: 28925073
Rieth A, Richter MJ, Gall H, Seeger W, Ghofrani HA, Mitrovic V, Hamm CW (2017) Hemodynamic phenotyping based on exercise catheterization predicts outcome in patients with heart failure and reduced ejection fraction. J Heart Lung Transplant 36(8):880–889. https://doi.org/10.1016/j.healun.2017.02.022
doi: 10.1016/j.healun.2017.02.022 pubmed: 28342708
Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69(13):1718–1734. https://doi.org/10.1016/j.jacc.2017.01.051
doi: 10.1016/j.jacc.2017.01.051 pubmed: 28359519
Guazzi M, Bandera F, Pelissero G, Castelvecchio S, Menicanti L, Ghio S, Temporelli PL, Arena R (2013) Tricuspid annular plane systolic excursion and pulmonary arterial systolic pressure relationship in heart failure: an index of right ventricular contractile function and prognosis. Am J Physiol Heart Circ Physiol 305(9):H1373-1381. https://doi.org/10.1152/ajpheart.00157.2013
doi: 10.1152/ajpheart.00157.2013 pubmed: 23997100
Tello K, Wan J, Dalmer A, Vanderpool R, Ghofrani HA, Naeije R, Roller F, Mohajerani E, Seeger W, Herberg U, Sommer N, Gall H, Richter MJ (2019) Validation of the tricuspid annular plane systolic excursion/systolic pulmonary artery pressure ratio for the assessment of right ventricular-arterial coupling in severe pulmonary hypertension. Circ Cardiovasc Imaging. https://doi.org/10.1161/CIRCIMAGING.119.009047
doi: 10.1161/CIRCIMAGING.119.009047 pubmed: 31718275 pmcid: 7099862
Guazzi M, Dixon D, Labate V, Beussink-Nelson L, Bandera F, Cuttica MJ, Shah SJ (2017) RV contractile function and its coupling to pulmonary circulation in heart failure with preserved ejection fraction: stratification of clinical phenotypes and outcomes. JACC Cardiovasc Imaging 10(10 Pt B):1211–1221. https://doi.org/10.1016/j.jcmg.2016.12.024
doi: 10.1016/j.jcmg.2016.12.024 pubmed: 28412423
Guazzi M, Naeije R, Arena R, Corra U, Ghio S, Forfia P, Rossi A, Cahalin LP, Bandera F, Temporelli P (2015) Echocardiography of right ventriculoarterial coupling combined with cardiopulmonary exercise testing to predict outcome in heart failure. Chest 148(1):226–234. https://doi.org/10.1378/chest.14-2065
doi: 10.1378/chest.14-2065 pubmed: 25633590
Tello K, Axmann J, Ghofrani HA, Naeije R, Narcin N, Rieth A, Seeger W, Gall H, Richter MJ (2018) Relevance of the TAPSE/PASP ratio in pulmonary arterial hypertension. Int J Cardiol 266:229–235. https://doi.org/10.1016/j.ijcard.2018.01.053
doi: 10.1016/j.ijcard.2018.01.053 pubmed: 29887454
Gall H, Felix JF, Schneck FK, Milger K, Sommer N, Voswinckel R, Franco OH, Hofman A, Schermuly RT, Weissmann N, Grimminger F, Seeger W, Ghofrani HA (2017) The Giessen Pulmonary Hypertension Registry: survival in pulmonary hypertension subgroups. J Heart Lung Transplant 36(9):957–967. https://doi.org/10.1016/j.healun.2017.02.016
doi: 10.1016/j.healun.2017.02.016 pubmed: 28302503
Kovacs G, Herve P, Barbera JA, Chaouat A, Chemla D, Condliffe R, Garcia G, Grunig E, Howard L, Humbert M, Lau E, Laveneziana P, Lewis GD, Naeije R, Peacock A, Rosenkranz S, Saggar R, Ulrich S, Vizza D, Vonk Noordegraaf A, Olschewski H (2017) An official European Respiratory Society statement: pulmonary haemodynamics during exercise. Eur Respir J 50(5):1700578. https://doi.org/10.1183/13993003.00578-2017
doi: 10.1183/13993003.00578-2017 pubmed: 29167297
Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, Maron BA (2015) Protocol for exercise hemodynamic assessment: performing an invasive cardiopulmonary exercise test in clinical practice. Pulm Circ 5(4):610–618. https://doi.org/10.1086/683815
doi: 10.1086/683815 pubmed: 26697168 pmcid: 4671735
Kang G, Ha R, Banerjee D (2016) Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. J Heart Lung Transplant 35(1):67–73. https://doi.org/10.1016/j.healun.2015.06.009
doi: 10.1016/j.healun.2015.06.009 pubmed: 26212656
Armstrong HF, Schulze PC, Kato TS, Bacchetta M, Thirapatarapong W, Bartels MN (2013) Right ventricular stroke work index as a negative predictor of mortality and initial hospital stay after lung transplantation. J Heart Lung Transplant 32(6):603–608. https://doi.org/10.1016/j.healun.2013.03.004
doi: 10.1016/j.healun.2013.03.004 pubmed: 23566545 pmcid: 4945758
Medrek SK, Kloefkorn C, Nguyen DTM, Graviss EA, Frost AE, Safdar Z (2017) Longitudinal change in pulmonary arterial capacitance as an indicator of prognosis and response to therapy and in pulmonary arterial hypertension. Pulm Circ. https://doi.org/10.1177/2045893217698715
doi: 10.1177/2045893217698715 pubmed: 28597758 pmcid: 5467926
Oliveira RKF, Faria-Urbina M, Maron BA, Santos M, Waxman AB, Systrom DM (2017) Functional impact of exercise pulmonary hypertension in patients with borderline resting pulmonary arterial pressure. Pulm Circ 7(3):654–665. https://doi.org/10.1177/2045893217709025
doi: 10.1177/2045893217709025 pubmed: 28895507 pmcid: 5841910
Tello K, Richter MJ, Axmann J, Buhmann M, Seeger W, Naeije R, Ghofrani HA, Gall H (2018) More on single-beat estimation of right ventriculoarterial coupling in pulmonary arterial hypertension. Am J Respir Crit Care Med 198(6):816–818. https://doi.org/10.1164/rccm.201802-0283LE
doi: 10.1164/rccm.201802-0283LE pubmed: 29756988
Tedford RJ (2014) Determinants of right ventricular afterload (2013 Grover Conference series). Pulmonary circulation 4(2):211–219. https://doi.org/10.1086/676020
doi: 10.1086/676020 pubmed: 25006440 pmcid: 4070769
Saouti N, Westerhof N, Helderman F, Marcus JT, Boonstra A, Postmus PE, Vonk-Noordegraaf A (2010) Right ventricular oscillatory power is a constant fraction of total power irrespective of pulmonary artery pressure. Am J Respir Crit Care Med 182(10):1315–1320. https://doi.org/10.1164/rccm.200910-1643OC
doi: 10.1164/rccm.200910-1643OC pubmed: 20622041
Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M (2015) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 46(4):903–975. https://doi.org/10.1183/13993003.01032-2015
doi: 10.1183/13993003.01032-2015 pubmed: 26318161
Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM (2009) Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol 53(13):1119–1126. https://doi.org/10.1016/j.jacc.2008.11.051
doi: 10.1016/j.jacc.2008.11.051 pubmed: 19324256 pmcid: 2736110
Fonarow GC (2017) Refining classification of heart failure based on ejection fraction. JACC Heart Fail 5(11):808–809. https://doi.org/10.1016/j.jchf.2017.08.011
doi: 10.1016/j.jchf.2017.08.011 pubmed: 29096789
Cikes M, Solomon SD (2016) Beyond ejection fraction: an integrative approach for assessment of cardiac structure and function in heart failure. Eur Heart J 37(21):1642–1650. https://doi.org/10.1093/eurheartj/ehv510
doi: 10.1093/eurheartj/ehv510 pubmed: 26417058
Tumminello G, Lancellotti P, Lempereur M, D’Orio V, Pierard LA (2007) Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 28(5):569–574. https://doi.org/10.1093/eurheartj/ehl561
doi: 10.1093/eurheartj/ehl561 pubmed: 17314112
Kjaergaard J, Akkan D, Iversen KK, Kober L, Torp-Pedersen C, Hassager C (2007) Right ventricular dysfunction as an independent predictor of short- and long-term mortality in patients with heart failure. Eur J Heart Fail 9(6–7):610–616. https://doi.org/10.1016/j.ejheart.2007.03.001
doi: 10.1016/j.ejheart.2007.03.001 pubmed: 17462946
Gorter TM, Hoendermis ES, van Veldhuisen DJ, Voors AA, Lam CS, Geelhoed B, Willems TP, van Melle JP (2016) Right ventricular dysfunction in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Eur J Heart Fail 18(12):1472–1487. https://doi.org/10.1002/ejhf.630
doi: 10.1002/ejhf.630 pubmed: 27650220
Gorter TM, van Veldhuisen DJ, Bauersachs J, Borlaug BA, Celutkiene J, Coats AJS, Crespo-Leiro MG, Guazzi M, Harjola VP, Heymans S, Hill L, Lainscak M, Lam CSP, Lund LH, Lyon AR, Mebazaa A, Mueller C, Paulus WJ, Pieske B, Piepoli MF, Ruschitzka F, Rutten FH, Seferovic PM, Solomon SD, Shah SJ, Triposkiadis F, Wachter R, Tschope C, de Boer RA (2018) Right heart dysfunction and failure in heart failure with preserved ejection fraction: mechanisms and management. Position statement on behalf of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 20(1):16–37. https://doi.org/10.1002/ejhf.1029
doi: 10.1002/ejhf.1029 pubmed: 29044932
Harjola V-P, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O, Crespo-Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, Yilmaz MB, Konstantinides S (2016) Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail 18(3):226–241. https://doi.org/10.1002/ejhf.478
doi: 10.1002/ejhf.478
Champion HC, Michelakis ED, Hassoun PM (2009) Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications. Circulation 120(11):992–1007. https://doi.org/10.1161/CIRCULATIONAHA.106.674028
doi: 10.1161/CIRCULATIONAHA.106.674028 pubmed: 19752350
Rosenkranz S, Gibbs JS, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiery JL (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37(12):942–954. https://doi.org/10.1093/eurheartj/ehv512
doi: 10.1093/eurheartj/ehv512 pubmed: 26508169
Gorter TM, van Veldhuisen DJ, Voors AA, Hummel YM, Lam CSP, Berger RMF, van Melle JP, Hoendermis ES (2018) Right ventricular-vascular coupling in heart failure with preserved ejection fraction and pre- vs. post-capillary pulmonary hypertension. Eur Heart J Cardiovasc Imaging 19(4):425–432. https://doi.org/10.1093/ehjci/jex133
doi: 10.1093/ehjci/jex133 pubmed: 28531295
Bosch L, Lam CSP, Gong L, Chan SP, Sim D, Yeo D, Jaufeerally F, Leong KTG, Ong HY, Ng TP, Richards AM, Arslan F, Ling LH (2017) Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. Eur J Heart Fail 19(12):1664–1671. https://doi.org/10.1002/ejhf.873
doi: 10.1002/ejhf.873 pubmed: 28597497
Ghio S, Guazzi M, Scardovi AB, Klersy C, Clemenza F, Carluccio E, Temporelli PL, Rossi A, Faggiano P, Traversi E, Vriz O, Dini FL, all i, (2017) Different correlates but similar prognostic implications for right ventricular dysfunction in heart failure patients with reduced or preserved ejection fraction. Eur J Heart Fail 19(7):873–879. https://doi.org/10.1002/ejhf.664
doi: 10.1002/ejhf.664 pubmed: 27860029
Greenberg B (2017) Jumping down the rabbit hole: unravelling the right ventricle in heart failure. Eur J Heart Fail 19(12):1672–1674. https://doi.org/10.1002/ejhf.985
doi: 10.1002/ejhf.985 pubmed: 29027321
Gorter TM, Obokata M, Reddy YNV, Melenovsky V, Borlaug BA (2018) Exercise unmasks distinct pathophysiologic features in heart failure with preserved ejection fraction and pulmonary vascular disease. Eur Heart J 39(30):2825–2835. https://doi.org/10.1093/eurheartj/ehy331
doi: 10.1093/eurheartj/ehy331 pubmed: 29947750 pmcid: 6093469

Auteurs

Andreas J Rieth (AJ)

Department of Cardiology, Kerckhoff-Klinik GmbH, Benekestr 2-8, 61231, Bad Nauheim, Germany. a.rieth@kerckhoff-klinik.de.

Manuel J Richter (MJ)

Department of Pneumology, Kerckhoff-Klinik, Bad Nauheim, Germany.
Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany.

Khodr Tello (K)

Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany.

Henning Gall (H)

Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany.

Hossein A Ghofrani (HA)

Department of Pneumology, Kerckhoff-Klinik, Bad Nauheim, Germany.
Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany.
Department of Medicine, Imperial College London, London, UK.

Stefan Guth (S)

Department of Thoracic Surgery, Kerckhoff-Klinik, Bad Nauheim, Germany.

Christoph B Wiedenroth (CB)

Department of Thoracic Surgery, Kerckhoff-Klinik, Bad Nauheim, Germany.

Werner Seeger (W)

Department of Internal Medicine, Justus Liebig University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), member of the German Center for Lung Research (DZL), Giessen, Germany.

Steffen D Kriechbaum (SD)

Department of Cardiology, Kerckhoff-Klinik GmbH, Benekestr 2-8, 61231, Bad Nauheim, Germany.

Veselin Mitrovic (V)

Department of Cardiology, Kerckhoff-Klinik GmbH, Benekestr 2-8, 61231, Bad Nauheim, Germany.

P Christian Schulze (PC)

Department of Cardiology, University Hospital Jena, Jena, Germany.

Christian W Hamm (CW)

Department of Cardiology, Kerckhoff-Klinik GmbH, Benekestr 2-8, 61231, Bad Nauheim, Germany.
Department of Cardiology, Justus Liebig University Giessen, Universities of Giessen and Marburg, Giessen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH